Devyser Diagnostics Q2: Initial take – robust sales - Redeye

Redeye notes Q2 sales spot on our estimates, but an EBIT far from our expectations (though heavily impacted by transitory costs). Still, some of the more important pieces of the report are outside the numbers and point to a strong confidence from management to continue delivering strong sales growth and achieve its profitability target.

Länk till analysen i sin helhet: https://www.redeye.se/research/1025825/devyser-diagnostics-q2-initial-take-robust-sales?utm_source=finwire&utm_medium=RSS